Please Login or Register

Login|Register FREE

Please Login or Register

Login|Register FREE

About AVRO

AVROBIO, Inc., is a Phase 2 clinical stage gene therapy company focused on developing potentially curative lentiviral-based gene therapies to treat rare diseases following a single dose. AVROBIO's gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. AVROBIO is focused on the development of its gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.
Primary Exchange: NASDAQ
SIC Biological Products, (No Diagnostic Substances)
NAICS Biological Product (except Diagnostic) Manufacturing

AVRO is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
EQWS Invesco Russell 2000 Equal Weight ETF 20.4 M 2.04E+07 1,977 1977 0.02% 0.00021 4 K 4458
IWM iShares Russell 2000 ETF 43.3 B 4.33271E+10 2,021 2021 0.01% 0.0001 3.6 M 3583440
IWN iShares Russell 2000 Value ETF 9.3 B 9.25817E+09 1,372 1372 0.0% 0 253 K 252900
IWO iShares Russell 2000 Growth ETF 8.9 B 8.88998E+09 1,240 1240 0.01% 0.0001 1.2 M 1225350
IWV iShares Russell 3000 ETF 8.2 B 8.24012E+09 3,005 3005 0.0% 0 59 K 59356
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 1.8 B 1.8E+09 1,028 1028 0.01% 0.000116874 216 K 216277
URTY ProShares UltraPro Russell2000 99.5 M 9.9465E+07 2,033 2033 0.0% 1.36372E-05 5 K 5013
UWM ProShares Ultra Russell2000 153.7 M 1.53664E+08 2,032 2032 0.0% 2.98509E-05 10 K 10387

Wait, Before You Leave...